Clinical outcome and safety of rituximab therapy for pemphigoid diseases
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://data.mendeley.com/datasets/7j5vv3rryc
下载链接
链接失效反馈官方服务：
资源简介：
https://doi.org/10.1016/j.jaad.2019.11.023
Supplemental materials for this retrospective case series including all (n=38) pemphigoid patients at the University of Pennsylvania followed at least 1 year after RTX or until death. Outcomes followed consensus definitions. The primary endpoint was complete remission (CR). Secondary endpoints were CR off therapy (CROT), corticosteroid dose, relapse, serious adverse events (SAEs), and autoantibody titers.
创建时间：
2020-02-19
